{
    "2021-03-22": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Refusal to File",
                        "semaglutide",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Novo Nordisk A/S â€“ Share repurchase programme",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "share repurchase",
                        "programme"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}